

**Question for written answer E-004348/2026
to the Commission**

Rule 144

**Sérgio Humberto (PPE), Paulo Cunha (PPE), Paulo do Nascimento Cabral (PPE),
Sebastião Bugalho (PPE), Ana Miguel Pedro (PPE), Liesbet Sommen (PPE), Michalis
Hadjipantela (PPE), Elena Nevado del Campo (PPE), Hélder Sousa Silva (PPE), Dolors
Montserrat (PPE), Tomislav Sokol (PPE), Manuela Ripa (PPE), Lídia Pereira (PPE)**

Subject: Strategic orientation and results of EU funding for cancer research

Achieving the objectives of the Cancer Mission and Europe's Beating Cancer Plan calls for linking research priorities, financial resources and the application of knowledge in health systems.

It is important to ensure that EU funding follows well-defined strategic axes and that programmes have the right kind of indicators for the type of research and the time frames involved.

This evaluation should identify the concrete contribution of the research to improving prevention, diagnosis, treatment and quality of life for patients, including the reduction of low-value cancer care.

In view of the above:

1. How does the Commission ensure that EU funding for cancer research responds to clearly defined strategic priorities linked to the objectives of the European Mission on Cancer and Europe's Beating Cancer Plan?
2. What indicators and monitoring mechanisms does the Commission use to evaluate the results of the funded projects and their implementation in health systems, respecting the different time frames and degrees of uncertainty inherent in the research?
3. While respecting equal treatment and ensuring continuity of funding for strategic priorities, what mechanisms are available or planned to take advantage of proposals of high scientific quality that exceed the evaluation thresholds but do not receive funding due to insufficient budget?

Submitted: 22.10.2026